Hi Shell. My understanding is that companies will do their own...

First 7 Last

Share
Profile

Follow
BigDaniel

3,870 Posts.

3205

12/06/22

11:22

Post #: 61963159
Share

Originally posted by Shellbell ↑

I checked to confirm if we are likely to do our manufacturing at Peter Mac and it certainly appears that way.

https://www.petermac.org/news/miles...-t-cell-therapy-manufacturing-license-awarded August 29, 2019

Peter MacCallum Cancer Centre welcomes the issuing of the first license to manufacture commercial T-Cell treatments, including breakthrough CAR T-Cell therapies, within Australia. The Therapeutic Goods Administration has awarded a T-Cells GMP manufacturing licence to Cell Therapies Pty Ltd, a company which is situated at Peter Mac.

I don't think we can underestimate the partnership we have Peter Mac and the ongoing support and fantastic position it puts Prescient. The following is Peter Mac's specialty division "Cell Therapies"

https://www.petermac.org/about/partnerships/cell-therapies
What's your take on the role that Peter Mac is likely to play in our monetization of Cell Pryme? I would imagine that we would need some sort contractural agreement of sort with Peter Mac. I can't imagine Peter Mac not wanting to use our cell manufacturing technology given its superirity, do you?

PS: I reckon @Un1qu3Nam3 deserves the Freddo Frog for Cell Pryme - A being the "Application" part of the equation. And, I reckon Steve enjoyed dangling that one out there for us as a bit of a guessing game.

Expand

Hi Shell.

My understanding is that companies will do their own manufacturing.

The monetisation would likely be via licensing the IP, not the actual cell therapy itself.

So Peter MacCallum role in monetisation I'd imagine would be nil, except for the vote of confidence after being the first facility to incorporate CellPryme into therapies. Also it's PTX IP solely, so no contract needed with Peter MacCullum.

CellPryme is a minor adjustment in the current standard practice of cell manufacturing for CAR-T therapies. It makes sense to me that companies that pay 'Prescient Therapeutics' for technique do their own manufacturing, you can't go flying batches of cells around the world.

But absolutely, Peter MacCallum will be the place PTX manufacturers it's CAR-T therapies incorporating CellPrym. At the very least until OmniCar moves to an international registrational trial which I'm confident it will, by which stage it will probably be worth $5B-$10B.

Cheers.

Last edited by BigDaniel: 12/06/22

PTX Price at posting: 19.0¢ Sentiment: Buy Disclosure: Held
18 Upvote

0 Great analysis

Reply